Impulse Dynamics Closes $60 Million Financing
01/12/21, 1:11 PM
Money raised
$60 million
Impulse Dynamics, a company dedicated to helping healthcare providers improve the lives of people with heart failure, today announced the completion of a $60 million supplemental Series D crossover financing with new investors, anchored by CR-CCT Industry Pilot Fund together with Redmile Group and Perceptive Advisors. Proceeds of the financing will be used for general corporate purposes, including acceleration of clinical and product development activities along with continued U.S. commercialization of the Optimizer® Smart, an FDA-approved implantable device for treating chronic heart failure that has been proven to strengthen the heart and help it beat more forcibly. The transaction closed in late December.
Company Info
Additional Info
The AIM HIGHer trial is a 1,500-patient quadruple-blind, sham-controlled trial that the company has initiated to evaluate the potential of CCM therapy to improve performance and reduce cardiovascular morbidity and mortality in HF patients with left ventricular ejection fraction of 40 to 60 percent. The company pioneered CCM® therapy, which is delivered by the company’s Optimizer® Smart system, an FDA-approved treatment verified to improve the quality of life for heart failure patients. Impulse Dynamics, a global medical device company dedicated to improving the lives of people with heart failure (HF), is proud to announce today the completion of a $101 million financing round comprised of both equity and debt.